Non-invasive diabetes device developer Sensys relocates to UK

NOVEMBER 21, 2008 -- Sensys Medical (Chandler, AZ), developer of non-invasive blood glucose monitoring technology, is relocating its world headquarters to the UK according to UK Trade and Investment. Sensys's device is able to read blood glucose levels an unlimited number of times a day via near-infrared spectrometry, and is expected to greatly enhance management of blood sugar levels for diabetes patients.

NOVEMBER 21, 2008 -- Sensys Medical (Chandler, AZ), developer of non-invasive blood glucose monitoringtechnology, is relocating its world headquarters to the UK according to UK Trade and Investment. Sensys's device is able to read blood glucose levels an unlimited number of times a day via near-infrared spectrometry, and is expected to greatly enhance diabetes management.

According to Robert Curry, CEO of Sensys Medical, "Moving to the UK is an exciting step for us as a business focused on the global diabetes epidemic. We believe that the UK represents the best hub to build a world-class medical device company. It provides us with crucial access to markets such as China, where it's estimated that during the 21st century almost a million new cases of diabetes will occur each year. "Our plan is to be well established commercially in Europe, the US and the Middle East over the next few years, and from that base to launch into India and China." Sensys Medical Ltd (Sensys UK), anticipates hiring 20-30 individuals from within the UK over the coming months.

The company was aided by UK Trade and Investment's Global Entrepreneur Programme (GEP) in making the move. Clinical trials of the technology are due to begin towards the end of 2009, with CE mark approval due by April of 2010.

To accelerate the adoption of its technology, Sensys UK has initiated a review with Great Britain's National Health Service (NHS) Technology Adoption Centre with the help of UK Trade and Investment. The process will yield a roadmap for commercializing the technology, which is expected to drive cost savings for the NHS. Sensys has also met with the UK Diabetes Research Network Coordinating Centre based at Imperial College in London, which will provide a clinical trial site as part of the company's pivotal clinical trial for regulatory approval by both the CE authorities and the US Food and Drug Administration.

More information:
UK Trade and Investment

More in Home